LV Liberty Vision Model 1 90Yttrium Brachytherapy Source

FDA 510(k) K193602 · Lv Liberty Vision Corporation

Substantially Equivalent

510(k) numberK193602

Submission

Device name
LV Liberty Vision Model 1 90Yttrium Brachytherapy Source
Applicant
Lv Liberty Vision Corporation
Portsmouth, NH, US
Received
December 23, 2019
Decision date
May 29, 2020
Decision
Substantially Equivalent (SESE)
Type
Special 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
KXK – Source, Brachytherapy, Radionuclide
Device class
Class II (moderate risk)
Regulation
21 CFR 892.5730
Specialty
Radiology
Implant
Yes

Other 510(k)s with product code KXK

510(k)DeviceApplicantDecision
K252296OncoPatchKXK · Traditional Oncopatch, Inc.12/05/2025SE
K242818IsoSphereKXK · Traditional Isoaid, LLC07/15/2025SE
K223465RadianceTx Radionuclide Brachytherapy SourceKXK · Traditional Radiance Therapeutics, Inc.01/11/2023SE
K221539GammaTileKXK · Traditional Gt Medical Technologies11/09/2022SE
K202267Sirius MRI Markers, Cs-131 Preloaded Strands with Sirius MRI Markers in 18 Gauge NeedlesKXK · Traditional Isoray Medical, Inc.12/31/2020SE
K190839GammaTileKXK · Traditional Gt Medical Technologies01/23/2020SE
K191324CivaDermKXK · Traditional Civatech Oncology, Inc.09/20/2019SE
K190296GammaTileKXK · Special Gt Medical Technologies03/13/2019SE
K180515GammaTileKXK · Traditional Isoray Medical, Inc.07/06/2018SE
K171487Sirius MRI Marker NSKXK · Traditional C4 Imaging, LLC08/25/2017SE

More from C4 Imaging, LLC

510(k)DeviceDecision
K163572LV Liberty Vision Model 1 90 Yttrium Brachytherapy SourceKXK · Traditional 03/15/2017SE

Questions and answers

When was LV Liberty Vision Model 1 90Yttrium Brachytherapy Source cleared by the FDA?

LV Liberty Vision Model 1 90Yttrium Brachytherapy Source (K193602) received a 510(k) decision of Substantially Equivalent on May 29, 2020, 158 days after the submission was received.

What is the product code of K193602?

The FDA product code is KXK – Source, Brachytherapy, Radionuclide, a Class II (moderate risk) device regulated under 21 CFR 892.5730.